Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group

Author:

Noort Sanne1,Zimmermann Martin2,Reinhardt Dirk3,Cuccuini Wendy4,Pigazzi Martina5,Smith Jenny6,Ries Rhonda E.6,Alonzo Todd A.7,Hirsch Betsy7,Tomizawa Daisuke8ORCID,Locatelli Franco910,Gruber Tanja A.11,Raimondi Susana12,Sonneveld Edwin13,Cheuk Daniel K.14,Dworzak Michael15,Stary Jan16,Abrahamsson Jonas17,Arad-Cohen Nira18,Czogala Malgorzata19,De Moerloose Barbara20,Hasle Henrik21ORCID,Meshinchi Soheil622,van den Heuvel-Eibrink Marry123,Zwaan C. Michel123

Affiliation:

1. Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s Hospital Rotterdam, Rotterdam, The Netherlands;

2. Department of Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany;

3. Acute Myeloid Leukemia-Berlin-Frankfurt-Münster Study Group, Pediatric Hematology and Oncology, Essen, Germany;

4. Department of Cytogenetics, Saint Louis Hospital, Paris, France;

5. Women and Children’s Health, Hematology-Oncology Laboratory, University of Padova, Padova, Italy;

6. Fred Hutchinson Cancer Research Center, Seattle, WA;

7. Children's Oncology Group, Monrovia, CA;

8. Division of Leukemia and Lymphoma, Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan;

9. Department of Pediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Pediatrico Bambino Gesù, Rome, Italy;

10. Department of Pediatric Sciences, University of Pavia, Pavia, Italy;

11. Department of Oncology and

12. Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN;

13. Dutch Childhood Oncology Group, The Hague, The Netherlands;

14. Department of Pediatrics and Adolescent Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong;

15. Department of Pediatrics, Children’s Cancer Research Institute and St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria;

16. Czech Pediatric Hematology/Oncology, University Hospital Motol and Charles University, Prague, Czech Republic;

17. Nordic Society for Pediatric Hematology and Oncology, Department of Pediatrics, Institution for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;

18. Pediatric Hemato-Oncology Department, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel;

19. Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland;

20. Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium;

21. Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark;

22. Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA; and

23. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

Abstract

Key Points t(16;21) translocations in AML comprise t(16;21)(p11;q22) (FUS-ERG) as well as t(16;21)(q24;q22) (RUNX1-CBFA2T3). Survival in pediatric AML with FUS-ERG is poor, whereas survival in RUNX1-CBFA2T3 is similar to other core-binding factor leukemias.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3